MTA Ancillary Agreement: IGBMC Cre-ERT2
Please consult the UBMTA for definitions of ORIGINAL MATERIAL, MATERIAL, MODIFICATIONS, RECIPIENT, and COMMERCIAL PURPOSES regarding this transfer of the ORIGINAL MATERIAL.
The ORIGINAL MATERIAL contains the Cre-ERT2 construct, designed by the Institut de Genetique et de Biologie Moleculaire et Cellulaire GIE-CERBM (IGBMC), Parc d'Innovation, BP 10142, 67404 Illkirch Cedex, France. The use of Cre-ERT2 transgenic mice is covered by US patent 7112715 and European patent IB01/02246, assigned to IGBMC.
Without written permission from IGBMC, RECIPIENT cannot use, directly or indirectly, the MATERIAL or any derived Cre-ERT2-containing transgenic mice for COMMERCIAL PURPOSES.
RECIPIENT may transfer MATERIAL, MODIFICATIONS, and/or derived Cre-ERT2-containing transgenic mice to other scientists at non-profit institutions ("Collaborator") for non-industrially sponsored research, non-commercial, internal, and academic research if, and only if, Collaborator has obtained a Cre-ERT2 MTA from IGBMC (please contact [email protected] to obtain a copy of the MTA). Notwithstanding the above, RECIPIENT may deposit plasmids derived from ORIGINAL MATERIAL to Addgene solely for the purpose of distributing to other academic and non-profit institutions. Distribution of the MATERIAL, MODIFICATIONS, and/or derived Cre-ERT2-containing transgenic mice to any party for COMMERCIAL PURPOSES is strictly prohibited.
In the event of any conflict between this Ancillary Agreement and the UBMTA, this Ancillary Agreement shall take precedence.